Endurance RP (HK:0575)
:0575
Want to see HK:0575 full AI Analyst Report?
Top Page
Endurance RP
(0575)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.93
▼(-8.73% Downside)
Action:UpgradedDate:12/03/25
The overall stock score is primarily impacted by significant financial challenges, including negative equity and persistent losses. While technical indicators show bullish momentum, the overbought RSI suggests caution. The negative P/E ratio further highlights valuation concerns.
Positive Factors
Revenue Growth
Sustained, high double‑digit revenue growth demonstrates accelerating demand and market traction. A growing top line provides room to scale fixed costs, improve unit economics, and fund strategic initiatives, forming a durable basis for eventual margin recovery if maintained.
Negative Factors
Negative Equity / Balance Sheet Risk
Negative stockholders' equity reflects accumulated deficits that erode the capital base and increase insolvency risk. This structural weakness constrains borrowing, investor confidence, and strategic options, and may force recapitalization or restructuring within a multi‑month horizon if not remedied.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained, high double‑digit revenue growth demonstrates accelerating demand and market traction. A growing top line provides room to scale fixed costs, improve unit economics, and fund strategic initiatives, forming a durable basis for eventual margin recovery if maintained.
Read all positive factors
Endurance RP (0575) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$204.27M
Dividend YieldN/A
Average Volume (3M)22.97K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth334.18%
EPS Growth73.87%
CountryHK
Employees18
SectorHealthcare
Sector Strength45
IndustryAsset Management
Share Statistics
EPS (TTM)-0.07
Shares Outstanding291,815,800
10 Day Avg. Volume10,410
30 Day Avg. Volume22,966
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-1.82
Price to Sales (P/S)14.92
P/FCF Ratio-2.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Endurance RP Business Overview & Revenue Model
Company Description
Endurance RP Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in the People's Republic of China, Europe, Hong Kong, and Taiwan. The company operates in two segments, Biopharma and Corporate Inve...
How the Company Makes Money
Endurance RP generates revenue through multiple streams, primarily from direct sales of its high-performance sports equipment and apparel through both online and physical retail channels. The company also offers subscription-based personalized tra...
Endurance RP Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 913.00K | 719.00K | 382.00K | 114.00K | 3.25M | 1.67M |
| Gross Profit | 118.00K | -219.00K | -2.34M | -1.11M | 850.00K | -788.00K |
| EBITDA | 18.49M | 18.01M | -7.72M | -9.56M | 10.38M | -4.48M |
| Net Income | -4.08M | -4.48M | -25.05M | -36.43M | -12.60M | -24.40M |
Balance Sheet | ||||||
| Total Assets | 734.00K | 610.00K | 2.79M | 26.32M | 62.23M | 80.31M |
| Cash, Cash Equivalents and Short-Term Investments | 147.00K | 121.00K | 2.42M | 1.41M | 11.13M | 5.21M |
| Total Debt | 1.77M | 3.34M | 1.20M | 13.73M | 14.01M | 14.01M |
| Total Liabilities | 4.90M | 6.51M | 4.35M | 23.72M | 23.46M | 30.00M |
| Stockholders Equity | -4.17M | -5.90M | -1.55M | 2.60M | 38.77M | 50.30M |
Cash Flow | ||||||
| Free Cash Flow | -3.75M | -4.13M | -3.59M | 533.00K | -1.75M | -5.73M |
| Operating Cash Flow | -3.73M | -4.13M | -3.59M | 545.00K | -1.70M | -5.72M |
| Investing Cash Flow | -233.00K | -3.00K | -1.00K | -7.00K | 123.00K | 1.83M |
| Financing Cash Flow | 3.84M | 2.14M | 5.58M | -795.00K | -782.00K | 6.54M |
Endurance RP Technical Analysis
Negative
1.02
Price Trends
0.88
Negative
0.91
Negative
0.87
Negative
Market Momentum
-0.06
Positive
18.30
Positive
28.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0575, the sentiment is Negative. The current price of 1.02 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.88, and above the 200-day MA of 0.87, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 18.30 is Positive, neither overbought nor oversold. The STOCH value of 28.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0575.
Endurance RP Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$153.62M | 2.94 | 9.71% | ― | 38.96% | 700.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$108.70M | -2.44 | -3218.89% | ― | ― | ― | |
48 Neutral | HK$204.27M | -7.62 | ― | ― | 334.18% | 73.87% | |
48 Neutral | HK$190.14M | 25.94 | -2.86% | ― | 78.92% | 75.20% | |
46 Neutral | HK$267.84M | 19.84 | 44.48% | ― | 56.79% | ― | |
42 Neutral | HK$281.29M | -0.32 | -31.83% | ― | 154.99% | 32.20% |
* Healthcare Sector Average
HK:0575
Endurance RP
0.70
0.22
47.37%
HK:0129
Asia Standard International Group
0.20
-0.13
-39.69%
HK:1217
China Innovation Investment Limited
0.01
<0.01
18.18%
HK:1835
Shanghai Realway Capital Assets Management Co., Ltd. Class H
0.91
-0.86
-48.59%
HK:0310
Prosperity Investment Holdings Limited
0.18
0.08
78.00%
HK:0339
Core Economy Investment Group Limited
0.76
0.67
783.72%
Endurance RP Corporate Events
Regent Pacific Sets Out Enhanced Audit Committee Mandate and Structure
Dec 19, 2025
Regent Pacific Group Limited has formalised and updated the written terms of reference for its Audit Committee, setting out a clear mandate to oversee financial reporting, risk management and internal control systems, as well as the audit process....
Deep Longevity Expands into U.S. Market with Strategic Leadership Appointments
Dec 10, 2025
Deep Longevity has announced key leadership appointments as part of its strategic expansion into the U.S. market, with a commercial launch planned for early 2026. The company aims to secure over 50 enterprise clients by the end of 2026, focusing o...
Deep Longevity Announces Strategic U.S. Market Entry in 2026
Dec 1, 2025
Deep Longevity, a leader in AI-driven aging clocks and longevity science, is set to enter the U.S. market in Q1 2026, targeting the wellness sector valued at over $6.8 trillion. This strategic expansion aims to establish a U.S.-based sales team fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.